Please provide your email address to receive an email when new articles are posted on . Denosumab is associated with a greater increase in lumbar spine bone mineral density at 12 months compared with ...

Please provide your email address to receive an email when new articles are posted on . Cancer treatment-induced bone loss and skeletal-related events resulting from bone metastases cause significant ...

Patients with rheumatic diseases who are treated with denosumab (Prolia®, Xgeva®) either alone, or in combination with either biologic or non-biologic disease-modifying antirheumatic drugs (DMARDs), ...

Compared with oral bisphosphonates, denosumab reduced fracture risk among treatment-experienced postmenopausal women with osteoporosis. Treatment with denosumab vs oral bisphosphonates is associated ...

Adults with osteoporosis who receive denosumab vs bisphosphonates may have a lower long-term risk of developing knee osteoarthritis.

The study of postmenopausal women in Iran found the efficacy of the biosimilar was noninferior to the reference product and the safety was comparable after 18 months. As the global population ...

The discontinuation of denosumab, a biologic therapy that targets receptor activator of NF-κB ligand (RANKL; also known as TNFSF11), in the treatment of patients with osteoporosis has been discouraged ...

∇ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. LONDON, Dec. 2, 2025 /PRNewswire/ -- Accord Healthcare today announced the launch ...

Denosumab use was associated with a lower risk for incident diabetes among patients with osteoporosis. Denosumab use is associated with a lower risk for diabetes among patients with osteoporosis, ...

Many women on dialysis quickly developed severe hypocalcemia after starting denosumab (Prolia) for osteoporosis, Medicare data showed. During the first 12 weeks of treatment, 41.1% of women on ...

Sandoz shared that it has reached agreement with Amgen to resolve all patent disputes between the two companies relating to the Food and Drug Administration approved Sandoz denosumab biosimilars.